Levodopa in the treatment of Parkinson's disease: Current controversies

Authors

  • Manfred Gerlach PhD,

    1. Division of Clinical Neurochemistry, Department of Child and Adolescent Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität, Würzburg, Germany
    2. Department of Neurology, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
    3. Division of Clinical Neurochemistry, Department of Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität, Würzburg, Germany
    Search for more papers by this author
  • Heinz Reichmann MD,

    1. Division of Clinical Neurochemistry, Department of Child and Adolescent Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität, Würzburg, Germany
    2. Department of Neurology, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
    3. Division of Clinical Neurochemistry, Department of Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität, Würzburg, Germany
    Search for more papers by this author
  • Peter Riederer PhD

    1. Division of Clinical Neurochemistry, Department of Child and Adolescent Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität, Würzburg, Germany
    2. Department of Neurology, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
    3. Division of Clinical Neurochemistry, Department of Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität, Würzburg, Germany
    Search for more papers by this author

Abstract

Companion letters have been published in Movement Disorders: Current Controversies: Levodopa in the Treatment of Parkinson's Disease, by Sharma, Vassallo, and Ross and Reply: Levodopa in the Treatment of Parkinson's Disease, by Olanow, Agid, and Mizuno.

Ancillary